We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Tandem Diabetes Care Inc | NASDAQ:TNDM | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 1.90 | 4.51% | 44.05 | 42.27 | 43.97 | 44.38 | 42.39 | 42.39 | 1,285,559 | 00:38:23 |
From May 2023 to May 2024
By Ben Glickman
Tandem Diabetes Care said Tuesday the U.S. Food and Drug Administration cleared its Tandem Mobi insulin pump for people with diabetes age six and older.
The San Diego-based diabetes technology company said the Tandem Mobi, a miniature insulin pump controllable from a mobile app, is the world's smallest durable insulin-delivery system. Tandem said it expected a limited release of the product in late 2023, and full commercial availability by early 2024.
Tandem said the new product features a 200-unit insulin cartridge, and is small enough to fit in a coin pocket. The product uses Tandem's Control-IQ technology, an algorithm which deliveries regular insulin deliveries and predicts glucose levels.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 11, 2023 09:34 ET (13:34 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Tandem Diabetes Care Chart |
1 Month Tandem Diabetes Care Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
